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Abstract
Despite a high prevalence of sleep disruption among hematopoietic cell transplant (HCT) 
recipients, relatively little research has investigated its relationships with modifiable cognitive or 
behavioral factors or used actigraphy to characterize sleep disruption in this population. 
Autologous HCT recipients who were 6 to 18 months post-transplant completed self-report 
measures of cancer-related distress, fear of cancer recurrence, dysfunctional sleep cognitions, and 
inhibitory sleep behaviors upon enrollment. Patients then wore an actigraph for seven days and 
completed a self-report measure of sleep disruption on day seven of the study. Among the 84 
participants (age M=60, 45% female), 41% reported clinically-relevant sleep disruption. 
Examination of actigraph data confirmed that, on average, sleep was disrupted (wake after sleep 
onset M=66 minutes) and sleep efficiency was less than recommended (sleep efficiency M=78%). 
Cancer-related distress, fear of recurrence, dysfunctional sleep cognitions, and inhibitory sleep 
behaviors were related to self-reported sleep disruption (p’s < .05) but not objective sleep indices. 
Results suggest that many HCT recipients experience sleep disruption after transplant. Cancer-
related distress, fear of recurrence, dysfunctional sleep cognitions, and maladaptive sleep 
behaviors are related to self-reported sleep disruption and should be considered targets for 
cognitive behavioral intervention in this population.
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Introduction
Sleep disruption is one of the most common quality of life concerns following hematopoietic 
cell transplantation (HCT),1,2 with as many as 77% of patients reporting sleep difficulties.3 
Sleep disruption encompasses a variety of sleep complaints including insomnia, which is 
characterized by problems falling or staying asleep, waking earlier than planned, and/or 
experiencing non-restorative sleep.4 Faulhaber and colleagues found that 23% of HCT 
recipients between 1 and 10 years post-transplant reported problems with insomnia.5 
Moreover, it has been consistently demonstrated that sleep quality is worse among HCT 
recipients in the post-transplant period compared to healthy individuals.6–13
Most evidence regarding sleep disruption among HCT recipients comes from single-item 
measures incorporated into quality of life questionnaires. These studies may fail to capture 
the complexity of sleep issues. Additional methodological limitations include small sample 
sizes and assessment of sleep disruption utilizing mixed samples of autologous and 
allogeneic transplant recipients. Autologous transplant recipients may experience different 
rates of sleep disruption than allogeneic recipients, who often receive steroids to treat 
GVHD, which may interfere with sleep. 26,27 Existing literature is also characterized by 
exclusive reliance upon self-reports to measure sleep problems with no use of currently 
available actigraph technology. Actigraphy, which involves the objective measurement of 
movement by means of an accelerometer14 has been successfully used to measure sleep/
wake patterns in cancer patients15–19 and correlates at a rate of about 90% agreement with 
polysomnography.20 Use of actigraphy is important to provide a more complete picture of 
sleep disruption among HCT patients.
Given the burden of sleep disruption among HCT patients, it is important to understand risk 
factors. Prior studies have often generally focused on demographic and clinical predictors.21 
For example, older age22,23 and female sex13,24,25 have been reported to be associated with 
worse sleep quality among HCT recipients. However, data are lacking regarding potentially 
modifiable risk factors. Cancer-related distress and fear of cancer recurrence have been 
associated with sleep disruption in breast cancer patients.28,29 In addition, evidence suggests 
that dysfunctional sleep-related thoughts and behaviors contribute to the perpetuation of 
insomnia symptoms in cancer patients and individuals without cancer.30–33 However, 
relationships between cognitive-behavioral factors and sleep disruption have not been 
investigated among HCT recipients.
The goals of the current study were to characterize the prevalence and severity of sleep 
disruption following autologous HCT measured subjectively and objectively as well as to 
examine the contribution of modifiable risk factors (i.e., cancer-related distress, fear of 
cancer recurrence, and dysfunctional sleep related thoughts and behaviors).
Materials and Methods
Participants
Participants were recruited from the Moffitt Cancer Center. Eligible participants: 1) were 
diagnosed with a hematologic malignancy, 2) were treated with autologous HCT 6 – 18 
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months prior to study enrollment, 3) were ≥18 years of age, 4) had no history of other 
cancers other than non-melanoma skin cancer, 5) had no evidence of disease progression at 
the time of study enrollment, 6) were able to speak and read English, and 7) were able to 
provide informed consent. The 6 to 18 month timeframe was chosen based on previous 
literature suggesting sleep quality remains relatively stable following day 100 post-
transplant44,45. Data were collected from May 2015 to February 2016.
Procedures
The study was approved by the University of South Florida Institutional Review Board. 
Eligibility was determined via medical record review in consultation with physicians and 
clinical staff. Patients were recruited during a scheduled outpatient appointment during 
which they completed an initial questionnaire assessing demographics, cancer-specific 
factors, and cognitive and behavioral factors related to sleep disruption. They then wore the 
actigraph for seven consecutive 24-hour periods and completed a sleep log used to aid in 
determination of bed and rise times. At the end of the monitoring period, participants 
completed a self-report measure of sleep keyed to the previous seven days.
Measures
Demographic and Clinical Characteristics: Participants completed a standardized self-
report form assessing age, sex, race, ethnicity, education, income, marital status, and 
employment status, a self-report version of the Eastern Cooperative Oncology Group 
(ECOG) performance status scale, and provided information on recent use of medications to 
promote sleep. Relevant clinical information (i.e., diagnosis, time since transplant) was 
collected via medical record review.
Cancer-related Distress: The intrusion subscale of the Impact of Events Scale (IES)34 is a 
7-item self-report measure assessing psychological distress during the past week. The 
measure was keyed to “cancer and its treatment.” Higher scores indicate greater distress.
Fear of Cancer Recurrence: The Fear of Cancer Recurrence Inventory (FCRI) is a 42-item 
self-report measure assessing fear or worry that cancer will return or progress.35 Higher 
scores indicate greater fear of recurrence.
Dysfunctional Beliefs and Attitudes About Sleep: The Dysfunctional Beliefs and 
Attitudes about Sleep scale (DBAS-16) is a 16-item, self-report measure assessing faulty 
beliefs, worries, and attentional biases surrounding sleep-related cognitions (e.g., After a 
poor night’s sleep, I know it will interfere with my activities the next day).36 Higher scores 
indicate more dysfunctional beliefs and attitudes about sleep.
Sleep Effort: The Glasgow Sleep Effort Scale (GSES) is a 7-item self-report measure 
assessing the extent to which individuals engage in effortful attempts to sleep (e.g., I put too 
much effort into sleeping when it should come naturally).37 Higher scores indicate greater 
sleep effort.
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Sleep Hygiene: The Sleep Hygiene Index (SHI) is a 13-item self-report measure assessing 
the extent to which individuals practice healthy behaviors that facilitate sleep and avoid 
behaviors that interfere with sleep (e.g., I go to bed at different times from day to day).38 
Higher scores indicate worse sleep hygiene.
Self-reported Sleep Disruption: The Insomnia Severity Index (ISI) is a 7-item self-report 
measure assessing the nature, severity, and impact of insomnia during the past week.39 
Higher scores indicate worse insomnia symptoms. Total ISI scores are interpreted as 
follows: 0–7 indicates no clinically significant insomnia, 8–14 indicates subthreshold 
insomnia, 15–21 indicates clinical insomnia (moderate severity), and 22–28 indicates 
clinical insomnia (severe).39
Objective Sleep Disruption: The Philips Respironics Actiwatch-Score (Philips Healthcare, 
Andover, MA) was used to objectively quantify sleep patterns. Participants were asked to 
wear the actigraph on their non-dominant wrist continuously for a seven-day period. 
Consistent with published recommendations41, sleep variables examined included sleep 
efficiency (i.e., percentage of time spent sleeping in relation to time spent in bed), sleep 
onset latency (SOL, i.e., amount of time taken to fall asleep), wake after sleep onset (WASO, 
i.e., minutes awake after an extended period of sleep), and total sleep time (TST, i.e., time 
spent asleep at night). Sleep efficiency served as the primary objective outcome of interest. 
We used sleep efficiency categories from the Pittsburgh Sleep Quality Index42 to categorize 
sleep efficiency in this population.
Statistical Analyses—Data were first examined for normality of distribution and outliers. 
Mean imputation was used to address sporadic missing items. Multiple imputation was used 
for scales for which all items were missing (SAS Institute Inc, 2011);43 the number of 
imputed data points never exceeded three participants per scale. Descriptive statistics were 
used to characterize the prevalence and severity of sleep disruption and the sleep indices that 
could be derived. Pearson correlation coefficients were used to examine relationships 
between sleep outcomes and demographic and clinical factors and the hypothesized cancer-
specific, cognitive, and behavioral risk factors.
Finally, a series of multivariable regression models were conducted to explore the variance 
in sleep disruption accounted for by demographic and clinical factors, cancer-specific 
factors, and cognitive and behavioral factors. Demographic and clinical factors significantly 
correlated with the outcome variables were entered into the first of these models. Cancer-
specific factors were then added to the second models. Finally, cognitive and behavioral 
factors were added to the final models. Data analyses were performed using SAS Version 9.4 
(Cary, NC). A p value < .05 (two-tailed) was considered statistically significant.
Results
Recruitment and Patient Characteristics
Supplemental Figure 1 depicts participant flow. Demographic and clinical characteristics of 
the sample (n=84) are shown in Table 1. Patients were an average of 60 years of age. The 
majority were male (55%), non-Hispanic (94%), white (87%), had completed some college 
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(64%), and were diagnosed with multiple myeloma (69%). At the time of participation, 
patients were an average of 350 days post-transplant and the majority reported they were not 
currently taking sleeping medication (61%).
Prevalence and Severity of Sleep Disruption and Hypothesized Risk Factors
The mean ISI score was 7.07 (SD=5.58); 41% of the sample reported clinically-significant 
sleep disruption (ISI total scores ≥ 8), with 30% meeting subthreshold insomnia, 10% 
moderate severity, and 1% severe insomnia. Actigraphy data indicated that, on average, 
patients took 20 minutes to fall asleep at night, spent approximately one hour awake after 
initially falling asleep, and spent 6.5 hours asleep. Overall, patients had a mean sleep 
efficiency of 78%, with 21% meeting sleep efficiency ratings of ≥85%, 50% in the 75 to 
84% range, 19% in the 65 to 74% range, and 10% <65%. HCT recipients’ subjective reports 
of sleep disruption were associated with objectively calculated total sleep time, p = .04; 
however, subjectively reported sleep was not associated with any of the other objective 
measure of sleep disruption, all p’s > .05.
On average, patients reported relatively low levels of intrusion (M = 10.53, SD = 8.21) and 
functional impairment from fear of cancer progression (M = 5.82, SD = 6.28) and moderate 
fear of cancer progression (M = 15.67, SD = 8.04). The average patient endorsed some 
dysfunctional beliefs and attitudes about sleep (M = 3.87, SD = 2.07) as well as sleep effort 
(M = 3.52, SD = 2.86) and relatively low levels of unhealthy sleep habits (M = 26.44, SD = 
5.39).
Risk Factors for Sleep Disruption
As shown in Table 2, subjective sleep disruption was not significantly associated with any 
demographic and clinical variables (p values > .05). Objective sleep disruption was 
significantly associated with age, ethnicity, and time since transplant. Specifically, younger 
patients and Hispanic patients demonstrated longer sleep onset latency (p values < .05). 
Hispanic patients also demonstrated worse sleep efficiency compared to non-Hispanic 
patients (p = .05). In addition, patients who had been transplanted more recently 
demonstrated shorter total sleep time (p < .05).
Relationships of cancer-specific risk factors with subjective and objective sleep disruption 
appear in Table 2. Intrusive psychological distress as measured by the IES and severity and 
functional impairment related to fear of cancer progression as measured by the FCRI were 
related to subjective sleep disruption (p values < .05). Functional impairments resulting from 
fear of cancer recurrence was related to longer sleep onset latency (p = .02). None of the 
other cancer-specific risk factors were significantly related with any of the objective indices 
of sleep disruption (p values > .05).
Relationships of cognitive and behavioral risk factors with subjective and objective sleep 
disruption appear in Table 2. Dysfunctional beliefs and attitudes about sleep as measured by 
the DBAS, sleep effort as measured by the GSES, and sleep hygiene as measured by the SHI 
were related to subjective sleep disruption (p values < .05). None of the cognitive and 
behavioral risk factors were related with any of the objective indices of sleep disruption (p 
values > .05).
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Multivariable Models with Risk Factors for Subjective Sleep Disruption
Table 3 shows results from the multivariable models with subjective sleep disruption as the 
outcome. No sociodemographic and clinical factors were related to subjective sleep 
disruption, therefore none were included. The block of variables including IES intrusion, 
FCRI severity, and FCRI functional impairment scores accounted for 8% of the variance in 
subjective sleep, with FCRI impairment being the only statistically significant predictor. 
Patients reporting greater functional impairment also reported worse subjective sleep 
disruption. When DBAS, GSES, and SHI were added to the model, all factors together 
accounted for 37% of the variance in subjective sleep (ΔR2 = 29%, F(6, 74) = 5.68, p < .
001), with GSES being the only statistically significant predictor. Patients reporting greater 
sleep effort reported worse subjective sleep disruption.
Multivariable Models with Risk Factors for Objective Sleep Disruption
Table 4 shows results from the multivariable models with objective sleep disruption as the 
outcome. In the first model, age and ethnicity were entered and accounted for 12% of the 
variance in sleep onset latency, with younger patients and Hispanic patients taking longer to 
fall asleep. In the second model, IES intrusion, FCRI severity, and FCRI functional 
impairment were added and accounted for an additional 9% of the variance in sleep onset 
latency; however, none of the added factors were statistically significant. In the final 
combined model, DBAS, GSES, and SHI were entered in addition to the other factors. All 
factors entered together accounted for 23% of variance in sleep onset latency, but ethnicity 
remained as the only statistically significant predictor.
Discussion
The present study characterized sleep disruption measured subjectively and objectively and 
examined potential demographic, clinical, cancer-specific, cognitive, and behavioral risk 
factors for sleep disruption among autologous HCT recipients between 6 and 18 months 
post-transplant. A total of 41% of patients reported clinically relevant sleep disruption. 
While estimates of the prevalence of sleep disruption in HCT patients vary widely, results 
from the present study are generally in line with estimates in the survivorship period 
following HCT.5,22,26,44,45 Actigraphy revealed that patients spent over an hour awake after 
falling asleep and spent an average of 6.5 hours asleep at night. Patients took approximately 
20 minutes to fall asleep at night and average sleep efficiency was 78%, which is below the 
recommended 85% often used as a cut point to indicate healthy sleep.46 Taken together, 
these descriptive data indicate that a large proportion of autologous HCT patients experience 
poor sleep.
In univariate analyses, cancer-specific, cognitive, and behavioral factors were associated 
with subjective but not objective sleep disruption. In multivariable models, only sleep effort 
as measured by the GSES emerged as a significant predictor of subjective sleep disruption. 
This pattern of results indicates that it may be patients’ distorted cognitions, more than 
cancer-related distress or unhealthy sleep habits that are the primary drivers of their self-
reported sleep disruption. If this is the case, it may be particularly important to change 
distorted cognitions in addressing HCT patients’ sleep complaints. In multivariable models 
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with objectively measured sleep onset latency as the outcome, demographic factors 
demonstrated the strongest relationship, with Hispanic ethnicity emerging as the only 
significant predictor of worse sleep onset latency. Randomized controlled trials of 
psychologically-based sleep interventions with cancer patients have generally demonstrated 
a reduction in objectively measured sleep disruption following intervention delivery.46–48 
However, these studies mostly recruited patients with breast cancer and therefore may not 
generalize to the autologous HCT setting.
The lack of relationship found between subjectively and objectively measured sleep is 
consistent with previous research and suggests that these two methods of sleep measurement 
assess different aspects of sleep. The finding that self-reported cognitive and behavioral 
factors were not associated with objective sleep in the present study raises the question of 
whether sleep interventions that target these mechanisms (e.g., CBT-I, MBSR) improve 
objective indices of sleep among autologous transplant recipients or may improve objective 
sleep through other mechanisms not assessed in this study (e.g., self-efficacy for managing 
sleep disturbance). Nevertheless, cancer-specific, cognitive, and behavioral factors were 
related to subjective reports of sleep, which is the more clinically-relevant outcome. No 
studies have been conducted of CBT-I or MBSR for sleep in HCT recipients. Because CBT-I 
and MBSR are evidenced-based treatments to improve sleep and, unlike medication, do not 
have the potential for side effects or dependency, they should still be considered for 
autologous HCT patients who report significant sleep disturbance.
Study limitations include the cross-sectional assessment of sleep, which prevented 
examination of how relationships between cancer-related, cognitive, and behavioral factors 
and sleep disruption change over time. Future research should examine changes in objective 
sleep longitudinally. The study was also limited by the lack of ethnic and racial diversity of 
its participants, which limits generalizability to other groups. In addition, the majority of the 
sample was diagnosed with multiple myeloma. Because autologous transplant is not curative 
for this disease cancer-related distress may be higher in these patients than in those with 
other diagnoses. Finally, other potential contributing factors (e.g., pain) were not assessed. 
Despite these limitations, the present study adds to a strong foundation of prior literature 
examining perpetuating factors of insomnia. Moreover, this study investigated not only 
subjective but also objective sleep disruption among a homogenous group of autologous 
transplant recipients, which to the best of our knowledge has not been done in HCT recipient 
survivorship.
In summary, patients reporting subjective sleep disruption should be referred for 
pharmacological or psychological sleep intervention after ruling out other concomitant 
medical conditions. Results from the present study suggest that a large proportion of 
autologous HCT recipients have dysfunctional cognitions about sleep and maladaptive sleep 
habits, both of which are targets for sleep interventions such as CBT-I. Moreover, CBT-I is a 
recommended treatment for clinical sleep issues in cancer patients.30,46,47 MBSR is another 
treatment with demonstrated efficacy among cancer patients.49,50 Future research should 
investigate the efficacy of interventions such as CBT-I and MBSR with autologous HCT 
recipients, particularly for those patients who report moderate to severe sleep disruption.
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Table 1
Demographic and Medical Characteristics (N = 84)
Characteristic
Age, years
 M 59.67
 SD 11.91
Gender, No. (%)
 Male 46 (54.8)
 Female 38 (45.2)
Ethnicity, No. (%)
 Not Hispanic 79 (94.0)
 Hispanic 4 (4.8)
 Missing 1 (1.2)
Race, No. (%)
 White 73 (86.9)
 Nonwhite 11 (13.1)
Marital Status, No. (%)
 Married 64 (76.2)
 Not married 20 (23.8)
Education, No. (%)
 High school or less 26 (31.0)
 College or more 34(67.8)
 Missing 1 (1.2)
Employment, No. (%)
 Work full-time or part-time 26 (31.0)
 Retired 32 (38.1)
 Other 25 (29.7)
 Missing 1 (1.2)
Income, No. (%)
 < 40K 31 (36.9)
 ≥ 40K 36 (42.9)
 Prefer Not To Answer/Missing 17 (20.2)
Cancer type, No. (%)
 Multiple Myeloma 58 (69.0)
 Hodgkin lymphoma 8 (9.5)
 Non-Hodgkin lymphoma 16 (19.1)
 Amyloidosis 2 (2.4)
Time since transplant, days
M 349.98
SD 123.89
Functional Status, No. (%)
 4 40 (47.6)
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Characteristic
 3 35 (41.7)
 2 6 (7.1)
 1 1 (1.2)
 Missing 2 (2.4)
Sleeping Medication, No. (%)
 Yes 32 (38.1)
 No 51 (60.7)
 Missing 1 (1.2)
Note. SD = standard deviation.
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Table 3
Multivariable Hierarchical Regression Models with Subjective Sleep Disruption
Risk Factors R2 β p
Cancer-Specific Risk Factors 0.08 - -
 IES Intrusion - 0.12 .36
 FCRI Severity - 0.05 .74
 FCRI Impairment - 0.25 .05
With Cognitive and Behavioral Factors 0.37 - -
 IES Intrusion - 0.05 .61
 FCRI Severity - −0.16 .18
 FCRI Impairment - 0.10 .29
 DBAS - 0.18 .11
 GSES - 0.55 < .001
 SHI - 0.04 .69
Note: IES = Impact of Events Scale, FCRI = Fear of Cancer Recurrence Inventory, DBAS = Dysfunctional Beliefs and Attitudes about Sleep, 
GSES = Glasgow Sleep Effort Scale, SHI = Sleep Habits Index.
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Table 4
Multivariable Hierarchical Regression Models with Sleep Onset Latency
Risk Factors R2 β p
Demographic & Clinical Risk Factors 0.12 - -
 Age - −0.22 .04
 Ethnicity - −0.27 .01
With Cancer-Specific Risk Factors 0.21 - -
 Age - −0.20 .05
 Ethnicity - −0.26 .01
 IES Intrusion - −0.20 .12
 FCRI Severity - 0.16 .26
 FCRI Impairment - 0.17 .16
With Cognitive and Behavioral Factors 0.23 - -
 Age - −0.20 .07
 Ethnicity - −0.28 .008
 IES Intrusion - −0.21 .10
 FCRI Severity - 0.11 .46
 FCRI Impairment - 0.14 .28
 DBAS - 0.08 .56
 GSES - 0.13 .41
 SHI - −0.06 .62
Note: SOL = Sleep Onset Latency, IES = Impact of Events Scale, FCRI = Fear of Cancer Recurrence Inventory, DBAS = Dysfunctional Beliefs and 
Attitudes about Sleep, GSES = Glasgow Sleep Effort Scale, SHI = Sleep Habits Index.
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